RxSight stock tumbles on reduced 2026 sales guidance By Investing.com
RxSight Inc. (NASDAQ:RXST) shares fell 12.9% after the company cut 2026 sales guidance to $110–$120M from $120–$135M, citing competitive headwinds in intraocular lenses. Total revenue guidance is $140–$160M, including $30–$40M from an Alcon collaboration. Preliminary Q2 2026 revenue is $32–$34M. Gross margin guidance raised to 73–75%.
How this was made
The 30-second read
Why it matters
The guidance reduction is the primary catalyst: it changes the expected 2026 revenue trajectory while the company simultaneously raises gross margin expectations and keeps operating expense guidance unchanged.
Market read
A concrete 2026 sales outlook cut (with quantified Q2 revenue expectations) is likely to drive valuation resets and near-term positioning in RXST.
What to watch
The revenue guidance includes $30–$40M from an Alcon collaboration; traders may need to assess whether competitive headwinds are temporary versus structural.
Background
RxSight is a medical technology company focused on Light Adjustable Lens products; it also references a strategic collaboration with Alcon.
Ticker impact
RxSight cut 2026 sales guidance to $110–$120M from $120–$135M, citing “meaningful commercial headwinds” in intraocular lenses.
Bearish bias for the next several sessions as traders reprice 2026 revenue expectations and margin/expense assumptions.
The article provides specific, time-relevant guidance changes (sales range cut) and quantifies expected Q2 revenue composition, which directly drives valuation and sentiment.
Market effects
Signals heightened competitive pressure in the intraocular lens market, potentially pressuring sentiment for similar medtech ophthalmology names.
Limited—primarily a US small/mid-cap medtech read-through within broader Nasdaq weakness.
Low—no cross-border regulatory or supply-chain shock described.
Counterpoint
Gross margin guidance was raised to 73%–75%, which could partially offset revenue disappointment if cost discipline holds.
Key entities
- companyRxSight Inc.
Lowered 2026 sales guidance and reported preliminary Q2 2026 revenue expectations amid competitive headwinds.
- partnerAlcon
Strategic collaboration referenced as contributing $30–$40M to 2026 revenue guidance and $5–$7M to Q2 revenue expectations.
